HANYANG GUAN^1,#, YUE WU^2,#, LU LI^3,#, YABING YANG¹, SHENGHUI QIU¹, ZHAN ZHAO¹, XIAODONG CHU¹, JIASHUAI HE¹, ZUYANG CHEN¹, YIRAN ZHANG¹, HUI DING¹, JINGHUA PAN^1,*, YUNLONG PAN^1,*

Oncology Research, Vol.31, No.4, pp. 437-448, 2023, DOI:10.32604/or.2023.029924

Abstract Neoantigen-targeted immunotherapy is a rapidly advancing field that holds great promise for treating cancer. The recognition of antigens by immune cells is a crucial step in tumor-specific killing, and neoantigens generated by mutations in cancer cells possess high immunogenicity and are selectively expressed in tumor cells, making them an attractive therapeutic target. Currently, neoantigens find utility in various domains, primarily in the realm of neoantigen vaccines such as DC vaccines, nucleic acid vaccines, and synthetic long peptide vaccines. Additionally, they hold promise in adoptive cell therapy, encompassing tumor-infiltrating cells, T cell receptors, and chimeric antigen receptors which are expressed by… More > Graphic Abstract

ZHIXIONG WANG^1,2, NA RISU², JIAYU FU², HUI LIU³, GUOMIN ZHOU³, QIAN LIU³, YAN ZOU⁴, JIAXING TANG⁴, LONG LI⁴, XUEKAI ZHU^4,*

BIOCELL, Vol.45, No.1, pp. 157-165, 2021, DOI:10.32604/biocell.2021.010261

Abstract Chimeric antigen receptor (CAR) T-cell therapy is mostly limited to hematological malignancies and has a poor effect on solid tumors. CAR T cells as a kind of immune cell may be affected by some immunomodulatory drugs such as pomalidomide, so the use of pomalidomide may improve the effect of CAR T cells on solid tumors. In this study, CD133- or HER2-specific CAR T cells were chosen to investigate whether pomalidomide can regulate the function of CAR T cells in vitro. We found that pomalidomide can significantly enhance the ability of CD133-CAR T cells and HER2-CAR T cells to kill tumor… More >